Kang Enbei: Amikacin Sulfate Injection is planned to win the bid for the tenth batch of national centralized drug purchase. On December 12th, Kang Enbei and its wholly-owned subsidiary Jinhua Kang Enbei participated in the bidding for the tenth batch of national centralized drug purchase organized by the National Joint Procurement Office for Centralized Drug Purchase and Use. After the bid opening and bid evaluation by the Joint Procurement Office, the company's product Amikacin Sulfate Injection plans to win the bid for this centralized procurement, and the supply provinces have been selected according to the market potential of each province. The successful results will be officially released after being publicized by the Joint Procurement Office. Amikacin sulfate injection is suitable for the treatment of serious infections caused by Pseudomonas aeruginosa, other Pseudomonas, Escherichia coli and other sensitive gram-negative bacilli and Staphylococcus (methicillin-sensitive strains). Compared with the original price, the price of the product to be selected this time has dropped to a certain extent.Bayrou was appointed as the new Prime Minister of France. French public opinion regards him as a staunch political ally of Macron. The Elysee Palace, the French presidential palace, announced on the 13th that President Macron appointed francois bayrou, chairman of the Democratic Movement Party, as the new Prime Minister on the same day, replacing Banier, who resigned after being impeached by the National Assembly. According to French media reports, Macron had a telephone conversation with Bayrou on the evening of 12th, and on the morning of 13th, Macron met Bayrou in the presidential palace and talked again. Macron subsequently announced the appointment decision. Bayrou became the fourth French prime minister this year. Beru founded the Democratic Movement Party, a centrist party, in 2007, and has served as its chairman ever since. In 2017, Bayrou announced that he would give up running for the French president, and formed an alliance with Macron, one of the popular candidates in the presidential election at that time and the chairman of the "Forward" movement, to fully support Macron's presidential election. In 2022, in the process of Macron's re-election, Bayrou led the Democratic Movement Party to continue to form an alliance with the ruling party. French public opinion regards Bayrou as a staunch political ally of Macron. (Xinhua News Agency)Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, while Contemporary Amperex Technology Co., Limited traded 175,000 shares today with a turnover of 44,625,200 yuan, accounting for 0.58% of the total turnover of the day. The average transaction price was 255 yuan, which was 4.51% lower than the market closing price of 267.03 yuan, of which the highest transaction price was 267.03 yuan and the lowest transaction price was 218.97 yuan.
Daye shares: the proposed acquisition of 100% equity of Al-Kogerte GmbH constitutes a major asset restructuring. Daye shares announced that the company intends to acquire 100% equity of Al-Kogerte GmbH in cash through its wholly-owned subsidiary RUNBO INT PTE.LTD, which constitutes a major asset restructuring of the company.Kexing launched the world's first phase III clinical study of bivalent inactivated enterovirus vaccine. On December 13th, the first volunteer was enrolled in the phase III clinical study of bivalent inactivated enterovirus vaccine developed by Beijing Kexing Biological Products Co., Ltd., a subsidiary of Kexing Holding Biotechnology Co., Ltd. (hereinafter referred to as "Kexing"). The vaccine is used to prevent hand, foot and mouth disease caused by enterovirus 71 (EV71) and coxsackie virus 16 (CA16). A multicenter, randomized, double-blind, controlled study design was adopted in this phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of the vaccine in children aged 6-71 months.
Canada recorded a monthly wholesale sales rate of 1% in October, the largest increase since April 2024. Canada recorded a monthly wholesale sales rate of 1% in October, with an expected 0.5% and a previous value of 0.80%. Canada's annual wholesale sales rate in October was 1.7%, and the previous value was -0.4%. Canada's annual wholesale inventory rate in October was -1%, and the previous value was 0.7%. The monthly rate of wholesale inventory in Canada in October was 0.9%, and the previous value was 0.2%. The monthly inventory rate of manufacturing industry in Canada in October was 0.2%, and the previous value was -0.4%. The monthly rate of new manufacturing orders in Canada in October was -0.9%, and the previous value was 3.9%. The monthly rate of unfinished orders in Canada's manufacturing industry in October was -0.2%, and the previous value was 1.6%. Canada's capacity utilization rate in the third quarter was 79.3%, with an expected 78.9% and a previous value of 79.10%. Canada's manufacturing inventory shipment ratio in October was 1.69%, and the previous value was 1.74%.CGNPC Delingha Photothermal Storage Integration Project was partially connected to the grid for power generation. The reporter learned from China Guangdong Nuclear Power Group Co., Ltd. that on December 13th, 800,000 kilowatts of photovoltaic power generation in CGNPC Delingha 1 million kilowatts Photothermal Storage Integration Project was partially connected to the grid for power generation. (Xinhua News Agency)State-owned Assets Supervision and Administration Commission (SASAC): Actively expand effective investment, improve investment efficiency, and focus on the layout of a number of major projects with strong traction and long-term benefits. The Party Committee of the State Council SASAC held a special meeting. The meeting stressed that it is necessary to promote central enterprises to improve their ability to cope with cyclical fluctuations, continue to exert efforts in performance appraisal, quality improvement and efficiency improvement, and economic operation, and strive to simultaneously improve efficiency and efficiency indicators, and strive to achieve development with stronger scientific and technological attributes and greater driving role; Actively expand effective investment, improve investment efficiency, focus on "two" and "two new" layout of a number of major projects with strong traction and long-term benefits; We will do a better job in helping small and medium-sized enterprises, promote central enterprises to deepen strategic cooperation in the industrial chain, take the lead in paying off debts owed by private enterprises, and go all out to stabilize employment, supply and flow, so as to better help the national economy continue to pick up. It is necessary to promote the central enterprises to improve the supply capacity of common technologies, further highlight the key points and strengthen the key core technologies, especially in areas with large investment and long cycle; Further highlight the original innovation, explore and create a "policy enclave", strengthen the applied basic research, and deeply root the "root technology"; Further highlight the transformation of achievements, promote the construction of a number of major pilot projects by central enterprises, and constantly open up the "last mile" of the transformation of scientific and technological achievements into real productive forces, so as to better help high-level science and technology stand on its own feet. (SASAC)
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14